2Bono AV. Leuprorelin-continuing advances in the treatment of prostate cancer. Bionledis,1997,2:4.
3okada H, Doken Y,Ogawa Y, et al, Sustaied suppresion of the pituitary gonadal axis by leuororelin three-month depot microspheeres in rats and dogs, Pharmaceutical Research, 1994,11:1199.
4Labrie F,Belanger A,Dupont A.et al.,Science behind total androgen btockade: from gene to combination therapy. Clin Invest Med,1993,16:475.
5Labrie F. At the cutting edge intracrinology.Molecular Cellular Endocrinology, 1991, 78:C113.
6Parmar H, Edwards L, Phillips RH, et al, Orchiectomy versus long-acting D-Trp-6-LHRH in advanced prostatic cancer. Br J Urol, 1987,59:248.
7Neumann F,Kalmus J. Physiological principles of androgen regulation in the hormonal treatment of sexual deviations. Berlio: Diesbach,1991.8-11.
8Niijima T,Aso Y. Clinical phase I ang phase Ⅱstudy on a sustrained release formulation of leuprorelin acetate (TAP- 144-SR) ,an LHIGH Agonist, in patients with promatic cancer. Acta Urotogica Japonica, 1990,36 : 1343.
9Kadar T,Redding TW,Ben D,et al. Receptots for prolactin,somatostatin,and luteininzing hormone in experimental prostate cancer after treatment with analogs of luteinizing hormonereleasing homone and sornatistatin. Proe Natl Acad Sci USA,1988,85:890.
10Paulson DF. Role of endocrine therapy in the managment of prostatic cancer in the skinnner and lieskovsky: Diagnosis and management of genitourinary cancer. Philadelphia: WB SaundersCo, 1988. 464-472.
